- ClearPoint Neuro press release ( NASDAQ: CLPT ): Q3 GAAP EPS of -$0.15. Revenue of $5.1M vs $4.6M.
- CLPT reaffirmed full year 2022 revenue outlook of between $21.0 and $22.0M.
- Cash and short-term investments totaled $40.5M as of Sept 30, 2022.
- CLPT said three new products were cleared by FDA in the quarter and are in the process of being deployed in limited market releases before the end of the year.
- "We achieved another strong quarter for revenue despite a historically high case cancellation rate and hospital supply chain disruptions." - President and CEO Joe Burnett
For further details see:
ClearPoint Neuro GAAP EPS of -$0.15, revenue of $5.1M